Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)

NCT ID: NCT02599961

Last Updated: 2020-06-11

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-09-10
• Study Completion Date: 2019-10-22

Brief Summary

The primary objective of the study is to evaluate the long-term safety of UX007 in Glut1 DS participants.

Detailed Description

The study will enroll up to 40 pediatric, adolescent and adult Glut 1 DS participants who have completed the UX007G-CL201 (NCT019933186) study and, at the discretion of the Sponsor, additional participants from other clinical studies, investigator sponsored trials (ISTs), or expanded access/compassionate use treatment.

Conditions

Glucose Transporter Type 1 Deficiency Syndrome

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

UX007

UX007 dosing targeted and/or maintained at 35% of total daily caloric intake.

Group Type: EXPERIMENTAL

UX007

Intervention Type: DRUG

UX007 is a liquid intended for oral (PO) administration.

Interventions

UX007

UX007 is a liquid intended for oral (PO) administration.

Intervention Type: DRUG

Other Intervention Names

Triheptanoin

Eligibility Criteria

Inclusion Criteria

• Diagnosis of Glut 1 DS confirmed by cerebrospinal fluid glucose concentration. erythrocyte 3-O-methyl-D-glucose uptake assay, or solute carrier family 2 member 1 (SLC2A1) molecular genetic testing (Information obtained from Medical Records)
• Males and females aged at least 1 year old at the time of informed consent
• Completion of UX007G-CL201 study (NCT01993186). Glut1 DS patients who received UX007/triheptanoin treatment as apart of clinical studies, ISTs or expanded access/compassionate use treatment programs may be eligible at the discretion of the Sponsor
• Provide written informed consent or verbal assent (if possible) with written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research related procedures
• Must, in the opinion of the investigator, be willing and able to complete all aspects of the study, and comply with accurate completion of the seizure diary
• Females of childbearing potential must have a negative urine pregnancy test at Baseline and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have not experienced menarche, are post-menopausal (defined as having no menses for at least 12 months without an alternative medical cause), or are permanently sterile due to total hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
• Participants of child-bearing potential or fertile males with partners of child-bearing potential who are sexually active must consent to use a highly-effective method of contraception as determined by the investigator from the period following the signing of the informed consent through 30 days after last dose of study drug.

Exclusion Criteria

• Any known hypersensitivity to triheptanoin, that in the judgement of the investigator, places the subject at an increased risk for adverse effects
• History of, or current suicidal ideation, behavior and/or attempts
• Pregnant and/or breast feeding an infant
• Unwilling or unable to discontinue use of prohibited medication (barbiturates, pancreatic lipase inhibitors) or other substance that may confound study objectives. Use of up to 3 concomitant antiepileptic drugs is allowed, provided dose has been stable at least 14 days prior to Baseline
• Use of any Investigational Product, drug or supplement (other than UX007) within 30 days prior to Baseline, or at any time during the study
• Has a condition of such severity and acuity, in the opinion of the investigator, that it warrants immediate surgical intervention or other treatment
• Has a concurrent disease or condition, or laboratory abnormality that, in the view of the investigator, places the subject at high risk of poor treatment compliance or of not completing the study, or would interfere with study participation or introduce additional safety concerns

• Minimum Eligible Age: 1 Year
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ultragenyx Pharmaceutical Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director

Role: STUDY_DIRECTOR

Ultragenyx Pharmaceutical Inc

Locations

Children's Hospital Colorado - University of Colorado, Denver, School of Medicine

Aurora, Colorado, United States

Miami Children's Hospital

Miami, Florida, United States

Columbia University Medical Center

New York, New York, United States

Cook Children's Medical Center

Fort Worth, Texas, United States

Seattle Children's Hospital

Seattle, Washington, United States

Melbourne Brain Centre

Heidelberg, Victoria, Australia

Copenhagen University Hospital

Copenhagen, , Denmark

Hospital Sant Joan De Deu

Barcelona, , Spain

The Newcastle upon Tyne Hospitals NHS Foundation Trust

Newcastle upon Tyne, , United Kingdom

Countries

United States; Australia; Denmark; Spain; United Kingdom

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

http://www.ultragenyx.com/

Company Website

Other Identifiers

2015-000389-69

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

UX007G-CL202

Identifier Type: -

Identifier Source: org_study_id